Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study.

BMC endocrine disorders

Pawaskar M, Bonafede M, Johnson B, Fowler R, Lenhart G, Hoogwerf B.
PMID: 23799930
BMC Endocr Disord. 2013 Jun 22;13:20. doi: 10.1186/1472-6823-13-20.

BACKGROUND: Type 2 diabetes is a common and costly illness, associated with significant morbidity and mortality. Despite this, there is relatively little information on the 'real-world' medication utilization patterns for patients with type 2 diabetes initiating exenatide BID or...

Cite
Pawaskar M, Bonafede M, Johnson B, et al. Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study. BMC Endocr Disord. 2013;13:20doi: 10.1186/1472-6823-13-20.
Pawaskar, M., Bonafede, M., Johnson, B., Fowler, R., Lenhart, G., & Hoogwerf, B. (2013). Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study. BMC endocrine disorders, 1320. https://doi.org/10.1186/1472-6823-13-20
Pawaskar, Manjiri, et al. "Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study." BMC endocrine disorders vol. 13 (2013): 20. doi: https://doi.org/10.1186/1472-6823-13-20
Pawaskar M, Bonafede M, Johnson B, Fowler R, Lenhart G, Hoogwerf B. Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study. BMC Endocr Disord. 2013 Jun 22;13:20. doi: 10.1186/1472-6823-13-20. PMID: 23799930; PMCID: PMC3750447.
Copy Download .nbib Format: NLM
Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes.

Clinical epidemiology

Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK, Nordstrom BL.
PMID: 29276410
Clin Epidemiol. 2017 Dec 14;9:679-688. doi: 10.2147/CLEP.S144368. eCollection 2017.

PURPOSE: To identify the characteristics and initial disease severity of patients with nonalcoholic fatty liver disease (NAFLD) and assess incidence and risk factors for disease progression in a retrospective study.METHODS: Patients ≥18 years of age without alcoholism or other...

Cite
Simeone JC, Bae JP, Hoogwerf BJ, et al. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol. 2017;9:679-688doi: 10.2147/CLEP.S144368.
Simeone, J. C., Bae, J. P., Hoogwerf, B. J., Li, Q., Haupt, A., Ali, A. K., Boardman, M. K., & Nordstrom, B. L. (2017). Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clinical epidemiology, 9679-688. https://doi.org/10.2147/CLEP.S144368
Simeone, Jason C, et al. "Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes." Clinical epidemiology vol. 9 (2017): 679-688. doi: https://doi.org/10.2147/CLEP.S144368
Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK, Nordstrom BL. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol. 2017 Dec 14;9:679-688. doi: 10.2147/CLEP.S144368. eCollection 2017. PMID: 29276410; PMCID: PMC5733910.
Copy Download .nbib Format: NLM
Public health in hospitals - can informatics bridge the gap?.

Future healthcare journal

Haroon S, Bhala N, Kumar KN, Wooldridge D, Hoogewerf J, Williams J.
PMID: 31098477
Future Healthc J. 2017 Oct;4(3):220-221. doi: 10.7861/futurehosp.4-3-220.

No abstract available.

Cite
Haroon S, Bhala N, Kumar KN, et al. Public health in hospitals - can informatics bridge the gap?. Future Healthc J. 2017;4(3):220-221doi: 10.7861/futurehosp.4-3-220.
Haroon, S., Bhala, N., Kumar, K. N., Wooldridge, D., Hoogewerf, J., & Williams, J. (2017). Public health in hospitals - can informatics bridge the gap?. Future healthcare journal, 4(3), 220-221. https://doi.org/10.7861/futurehosp.4-3-220
Haroon, Shamil, et al. "Public health in hospitals - can informatics bridge the gap?." Future healthcare journal vol. 4,3 (2017): 220-221. doi: https://doi.org/10.7861/futurehosp.4-3-220
Haroon S, Bhala N, Kumar KN, Wooldridge D, Hoogewerf J, Williams J. Public health in hospitals - can informatics bridge the gap?. Future Healthc J. 2017 Oct;4(3):220-221. doi: 10.7861/futurehosp.4-3-220. PMID: 31098477; PMCID: PMC6502573.
Copy Download .nbib Format: NLM
Predawn reflections on genetic studies of insulin-dependent diabetes mellitus.

Cleveland Clinic journal of medicine

Hoogwere B.
PMID: 3416410
Cleve Clin J Med. 1988 May-Jun;55(3):211-2.
Free Article

No abstract available.

Cite
Hoogwere B. Predawn reflections on genetic studies of insulin-dependent diabetes mellitus. Cleve Clin J Med. 1988;55(3):211-2
Hoogwere, B. (1988). Predawn reflections on genetic studies of insulin-dependent diabetes mellitus. Cleveland Clinic journal of medicine, 55(3), 211-2.
Hoogwere, B. "Predawn reflections on genetic studies of insulin-dependent diabetes mellitus." Cleveland Clinic journal of medicine vol. 55,3 (1988): 211-2.
Hoogwere B. Predawn reflections on genetic studies of insulin-dependent diabetes mellitus. Cleve Clin J Med. 1988 May-Jun;55(3):211-2. PMID: 3416410.
Copy Download .nbib Format: NLM
The Molecular Basis of the Chemokine/Chemokine Receptor Interaction-Scope for Design of Chemokine Antagonists.

Methods (San Diego, Calif.)

Wells TNC, Proudfoot AEI, Power CA, Lusti-Narasimhan M, Alouani S, Hoogewerf AJ, Peitsch MC.
PMID: 8812652
Methods. 1996 Aug;10(1):126-34. doi: 10.1006/meth.1996.0086.

Chemokines are a family of small proteins that are present in a variety of inflammatory conditions and have been shown to activate and recruit a wide variety of cell types. They bind to a family of seven transmembrane G-protein-coupled...

Cite
Wells TNC, Proudfoot AEI, Power CA, et al. The Molecular Basis of the Chemokine/Chemokine Receptor Interaction-Scope for Design of Chemokine Antagonists. Methods. 1996;10(1):126-34doi: 10.1006/meth.1996.0086.
Wells, T. N. C., Proudfoot, A. E. I., Power, C. A., Lusti-Narasimhan, M., Alouani, S., Hoogewerf, A. J., & Peitsch, M. C. (1996). The Molecular Basis of the Chemokine/Chemokine Receptor Interaction-Scope for Design of Chemokine Antagonists. Methods (San Diego, Calif.), 10(1), 126-34. https://doi.org/10.1006/meth.1996.0086
Wells, et al. "The Molecular Basis of the Chemokine/Chemokine Receptor Interaction-Scope for Design of Chemokine Antagonists." Methods (San Diego, Calif.) vol. 10,1 (1996): 126-34. doi: https://doi.org/10.1006/meth.1996.0086
Wells TNC, Proudfoot AEI, Power CA, Lusti-Narasimhan M, Alouani S, Hoogewerf AJ, Peitsch MC. The Molecular Basis of the Chemokine/Chemokine Receptor Interaction-Scope for Design of Chemokine Antagonists. Methods. 1996 Aug;10(1):126-34. doi: 10.1006/meth.1996.0086. PMID: 8812652.
Copy Download .nbib Format: NLM
Severe hypertriglyceridemia and acute pancreatitis during pregnancy: treatment with gemfibrozil.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Saadi HF, Kurlander DJ, Erkins JM, Hoogwerf BJ.
PMID: 15251700
Endocr Pract. 1999 Jan-Feb;5(1):33-6. doi: 10.4158/EP.5.1.33.

OBJECTIVE: To describe the effect of gemfibrozil therapy during pregnancy in a woman with severe hypertriglyceridemia.METHODS: We present a case report, with details of lipid levels throughout several attempted pregnancies, and discuss other similar published studies.RESULTS: In a 22-year-old...

Cite
Saadi HF, Kurlander DJ, Erkins JM, et al. Severe hypertriglyceridemia and acute pancreatitis during pregnancy: treatment with gemfibrozil. Endocr Pract. 1999;5(1):33-6doi: 10.4158/EP.5.1.33.
Saadi, H. F., Kurlander, D. J., Erkins, J. M., & Hoogwerf, B. J. (1999). Severe hypertriglyceridemia and acute pancreatitis during pregnancy: treatment with gemfibrozil. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 5(1), 33-6. https://doi.org/10.4158/EP.5.1.33
Saadi, H F, et al. "Severe hypertriglyceridemia and acute pancreatitis during pregnancy: treatment with gemfibrozil." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 5,1 (1999): 33-6. doi: https://doi.org/10.4158/EP.5.1.33
Saadi HF, Kurlander DJ, Erkins JM, Hoogwerf BJ. Severe hypertriglyceridemia and acute pancreatitis during pregnancy: treatment with gemfibrozil. Endocr Pract. 1999 Jan-Feb;5(1):33-6. doi: 10.4158/EP.5.1.33. PMID: 15251700.
Copy Download .nbib Format: NLM
Thyroid-stimulating antibody assay using a human thyrotropin receptor transfected cell line: relationship to clinical features of graves' disease.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Kim MR, Faiman C, Hoogwerf BJ, Gupta MK.
PMID: 15251770
Endocr Pract. 1997 Nov-Dec;3(6):337-43. doi: 10.4158/EP.3.6.337.

OBJECTIVE: To evaluate a Chinese hamster ovary cell line transfected with the human thyrotropin (thyroid-stimulating hormone or TSH) receptor (CHO-TSHR) for its use in routine clinical testing and compare it with the currently used Fisher rat thyroid cell line...

Cite
Kim MR, Faiman C, Hoogwerf BJ, et al. Thyroid-stimulating antibody assay using a human thyrotropin receptor transfected cell line: relationship to clinical features of graves' disease. Endocr Pract. 1997;3(6):337-43doi: 10.4158/EP.3.6.337.
Kim, M. R., Faiman, C., Hoogwerf, B. J., & Gupta, M. K. (1997). Thyroid-stimulating antibody assay using a human thyrotropin receptor transfected cell line: relationship to clinical features of graves' disease. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 3(6), 337-43. https://doi.org/10.4158/EP.3.6.337
Kim, M R, et al. "Thyroid-stimulating antibody assay using a human thyrotropin receptor transfected cell line: relationship to clinical features of graves' disease." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 3,6 (1997): 337-43. doi: https://doi.org/10.4158/EP.3.6.337
Kim MR, Faiman C, Hoogwerf BJ, Gupta MK. Thyroid-stimulating antibody assay using a human thyrotropin receptor transfected cell line: relationship to clinical features of graves' disease. Endocr Pract. 1997 Nov-Dec;3(6):337-43. doi: 10.4158/EP.3.6.337. PMID: 15251770.
Copy Download .nbib Format: NLM
Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus.

Clinical drug investigation

Neuser D, Benson A, Brückner A, Goldberg RB, Hoogwerf BJ, Petzinna D.
PMID: 17532702
Clin Drug Investig. 2005;25(9):579-87. doi: 10.2165/00044011-200525090-00003.

OBJECTIVE: To assess the safety profile of acarbose treatment over a 1-year period at a dose range of 50-300mg three times daily in patients with type 1 or type 2 diabetes mellitus.STUDY DESIGN AND PATIENTS: In this 56-week, double-blind,...

Cite
Neuser D, Benson A, Brückner A, et al. Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. Clin Drug Investig. 2005;25(9):579-87doi: 10.2165/00044011-200525090-00003.
Neuser, D., Benson, A., Brückner, A., Goldberg, R. B., Hoogwerf, B. J., & Petzinna, D. (2005). Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. Clinical drug investigation, 25(9), 579-87. https://doi.org/10.2165/00044011-200525090-00003
Neuser, Dieter, et al. "Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus." Clinical drug investigation vol. 25,9 (2005): 579-87. doi: https://doi.org/10.2165/00044011-200525090-00003
Neuser D, Benson A, Brückner A, Goldberg RB, Hoogwerf BJ, Petzinna D. Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. Clin Drug Investig. 2005;25(9):579-87. doi: 10.2165/00044011-200525090-00003. PMID: 17532702.
Copy Download .nbib Format: NLM
Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes.

Journal of diabetes science and technology

Nielsen LL, Okerson T, Holcombe J, Hoogwerf B.
PMID: 19885351
J Diabetes Sci Technol. 2008 Mar;2(2):255-60. doi: 10.1177/193229680800200214.

Obesity increases the risk of diabetes up to 90-fold and worsens hyperglycemia, hyperinsulinemia, insulin resistance, dyslipidemia, and nonalcoholic fatty liver disease. For patients with type 2 diabetes, weight loss can trigger improvements in all these conditions and decrease the...

Cite
Nielsen LL, Okerson T, Holcombe J, et al. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diabetes Sci Technol. 2008;2(2):255-60doi: 10.1177/193229680800200214.
Nielsen, L. L., Okerson, T., Holcombe, J., & Hoogwerf, B. (2008). Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. Journal of diabetes science and technology, 2(2), 255-60. https://doi.org/10.1177/193229680800200214
Nielsen, Loretta L, et al. "Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes." Journal of diabetes science and technology vol. 2,2 (2008): 255-60. doi: https://doi.org/10.1177/193229680800200214
Nielsen LL, Okerson T, Holcombe J, Hoogwerf B. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diabetes Sci Technol. 2008 Mar;2(2):255-60. doi: 10.1177/193229680800200214. PMID: 19885351; PMCID: PMC2771486.
Copy Download .nbib Format: NLM
Risk factors for 30-day readmission following hypoglycemia-related emergency room and inpatient admissions.

BMJ open diabetes research & care

Emons MF, Bae JP, Hoogwerf BJ, Kindermann SL, Taylor RJ, Nathanson BH.
PMID: 27110366
BMJ Open Diabetes Res Care. 2016 Apr 04;4(1):e000160. doi: 10.1136/bmjdrc-2015-000160. eCollection 2016.

OBJECTIVE: Hypoglycemia is a serious complication of diabetes treatment. This retrospective observational study characterized hypoglycemia-related hospital emergency room (ER) and inpatient (in-pt) admissions and identified risk factors for 30-day all-cause and hypoglycemia-related readmission.RESEARCH DESIGN AND METHODS: 4476 hypoglycemia-related ER...

Cite
Emons MF, Bae JP, Hoogwerf BJ, et al. Risk factors for 30-day readmission following hypoglycemia-related emergency room and inpatient admissions. BMJ Open Diabetes Res Care. 2016;4(1):e000160doi: 10.1136/bmjdrc-2015-000160.
Emons, M. F., Bae, J. P., Hoogwerf, B. J., Kindermann, S. L., Taylor, R. J., & Nathanson, B. H. (2016). Risk factors for 30-day readmission following hypoglycemia-related emergency room and inpatient admissions. BMJ open diabetes research & care, 4(1), e000160. https://doi.org/10.1136/bmjdrc-2015-000160
Emons, M F, et al. "Risk factors for 30-day readmission following hypoglycemia-related emergency room and inpatient admissions." BMJ open diabetes research & care vol. 4,1 (2016): e000160. doi: https://doi.org/10.1136/bmjdrc-2015-000160
Emons MF, Bae JP, Hoogwerf BJ, Kindermann SL, Taylor RJ, Nathanson BH. Risk factors for 30-day readmission following hypoglycemia-related emergency room and inpatient admissions. BMJ Open Diabetes Res Care. 2016 Apr 04;4(1):e000160. doi: 10.1136/bmjdrc-2015-000160. eCollection 2016. PMID: 27110366; PMCID: PMC4838663.
Copy Download .nbib Format: NLM
Real-World Glycemic Lowering Effectiveness of Linagliptin Among Adults with Type 2 Diabetes by Age, Renal Function, and Race.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Hoogwerf BJ, MacKenzie M, Sealls W, Cordova J, Gandhi P.
PMID: 32462538
Diabetes Ther. 2020 Jul;11(7):1527-1536. doi: 10.1007/s13300-020-00841-x. Epub 2020 May 27.

INTRODUCTION: To assess real-world effectiveness of linagliptin in persons with type 2 diabetes mellitus (T2DM) across a range of ages and renal function. Effectiveness was assessed in different races, with a focus on African Americans (AA).METHODS: This was a...

Cite
Hoogwerf BJ, MacKenzie M, Sealls W, et al. Real-World Glycemic Lowering Effectiveness of Linagliptin Among Adults with Type 2 Diabetes by Age, Renal Function, and Race. Diabetes Ther. 2020;11(7):1527-1536doi: 10.1007/s13300-020-00841-x.
Hoogwerf, B. J., MacKenzie, M., Sealls, W., Cordova, J., & Gandhi, P. (2020). Real-World Glycemic Lowering Effectiveness of Linagliptin Among Adults with Type 2 Diabetes by Age, Renal Function, and Race. Diabetes therapy : research, treatment and education of diabetes and related disorders, 11(7), 1527-1536. https://doi.org/10.1007/s13300-020-00841-x
Hoogwerf, Byron J, et al. "Real-World Glycemic Lowering Effectiveness of Linagliptin Among Adults with Type 2 Diabetes by Age, Renal Function, and Race." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 11,7 (2020): 1527-1536. doi: https://doi.org/10.1007/s13300-020-00841-x
Hoogwerf BJ, MacKenzie M, Sealls W, Cordova J, Gandhi P. Real-World Glycemic Lowering Effectiveness of Linagliptin Among Adults with Type 2 Diabetes by Age, Renal Function, and Race. Diabetes Ther. 2020 Jul;11(7):1527-1536. doi: 10.1007/s13300-020-00841-x. Epub 2020 May 27. PMID: 32462538; PMCID: PMC7324460.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries